Review



cervical vagal nerve stimulation  (Cyberonics Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Cyberonics Inc cervical vagal nerve stimulation
    Summary of clinical studies addressed to invasive cervical <t> vagal nerve stimulation </t> (iVNS) and primary headache disorders
    Cervical Vagal Nerve Stimulation, supplied by Cyberonics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cervical vagal nerve stimulation/product/Cyberonics Inc
    Average 90 stars, based on 1 article reviews
    cervical vagal nerve stimulation - by Bioz Stars, 2026-03
    90/100 stars

    Images

    1) Product Images from "Spotlight on cervical vagus nerve stimulation for the treatment of primary headache disorders: a review"

    Article Title: Spotlight on cervical vagus nerve stimulation for the treatment of primary headache disorders: a review

    Journal: Journal of Pain Research

    doi: 10.2147/JPR.S129202

    Summary of clinical studies addressed to invasive cervical vagal nerve stimulation (iVNS) and primary headache disorders
    Figure Legend Snippet: Summary of clinical studies addressed to invasive cervical vagal nerve stimulation (iVNS) and primary headache disorders

    Techniques Used: Functional Assay, Battery

    Summary of clinical studies addressed to non-invasive cervical vagal nerve stimulation (nVNS) for the treatment of episodic and chronic migraine
    Figure Legend Snippet: Summary of clinical studies addressed to non-invasive cervical vagal nerve stimulation (nVNS) for the treatment of episodic and chronic migraine

    Techniques Used: Functional Assay

    Summary of clinical studies addressed to non-invasive cervical vagal nerve stimulation (nVNS) for the treatment of episodic and chronic cluster headache
    Figure Legend Snippet: Summary of clinical studies addressed to non-invasive cervical vagal nerve stimulation (nVNS) for the treatment of episodic and chronic cluster headache

    Techniques Used: Functional Assay

    Schematic drawing of suspected distribution of VPAC1/2 and PAC 1 receptors subtype within the trigeminovascular complex and associated brain circuits. Notes: The parasympathetic neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylate cylase-activating peptide 38 (PACAP-38) interacts with receptor-subtype analysis (VPAC1/2, PAC 1) on a central and peripheral level. Neurogenic dural vasodilatation evoked by dural terminals of trigeminal nerve fibers was suppressed via PAC1-receptor subdomain. Intra-cerebral-ventricular application of PCAP-38, but not VIP, caused delayed activation and central sensitization of spontaneous TCC ring response (mainly via PAC1) along with increased responsiveness to intra- (dural-evoked) and extracranial (cutaneous) stimulation. From Akerman S, Goadsby PJ. Neuronal PAC1 receptors mediate delayed activation and sensitization of trigeminocervical neurons: Relevance to migraine. Sci Transl Med . 2015;7(308):308ra157. Reprinted with permission from AAAS. Abbreviations: SuS, nucleus salivatorius superior; TG, trigeminal ganglion; TCC, trigeminocervical complex; SPG, ganglion sphenopalatinum; PAG, periaquaeductal grey; LC, locus coeruleus; NRM, nucleus raphe magnus; Ach, acetylcholine; NKA, neurokrinin; CGRP, calcitonin gene-related peptide; SP, substance P.
    Figure Legend Snippet: Schematic drawing of suspected distribution of VPAC1/2 and PAC 1 receptors subtype within the trigeminovascular complex and associated brain circuits. Notes: The parasympathetic neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylate cylase-activating peptide 38 (PACAP-38) interacts with receptor-subtype analysis (VPAC1/2, PAC 1) on a central and peripheral level. Neurogenic dural vasodilatation evoked by dural terminals of trigeminal nerve fibers was suppressed via PAC1-receptor subdomain. Intra-cerebral-ventricular application of PCAP-38, but not VIP, caused delayed activation and central sensitization of spontaneous TCC ring response (mainly via PAC1) along with increased responsiveness to intra- (dural-evoked) and extracranial (cutaneous) stimulation. From Akerman S, Goadsby PJ. Neuronal PAC1 receptors mediate delayed activation and sensitization of trigeminocervical neurons: Relevance to migraine. Sci Transl Med . 2015;7(308):308ra157. Reprinted with permission from AAAS. Abbreviations: SuS, nucleus salivatorius superior; TG, trigeminal ganglion; TCC, trigeminocervical complex; SPG, ganglion sphenopalatinum; PAG, periaquaeductal grey; LC, locus coeruleus; NRM, nucleus raphe magnus; Ach, acetylcholine; NKA, neurokrinin; CGRP, calcitonin gene-related peptide; SP, substance P.

    Techniques Used: Activation Assay



    Similar Products

    cervical vagal nerve stimulation  (St Jude Medical)
    90
    St Jude Medical cervical vagal nerve stimulation
    Cervical Vagal Nerve Stimulation, supplied by St Jude Medical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cervical vagal nerve stimulation/product/St Jude Medical
    Average 90 stars, based on 1 article reviews
    cervical vagal nerve stimulation - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    cervical vagal nerve stimulation  (Cyberonics Inc)
    90
    Cyberonics Inc cervical vagal nerve stimulation
    Summary of clinical studies addressed to invasive cervical <t> vagal nerve stimulation </t> (iVNS) and primary headache disorders
    Cervical Vagal Nerve Stimulation, supplied by Cyberonics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cervical vagal nerve stimulation/product/Cyberonics Inc
    Average 90 stars, based on 1 article reviews
    cervical vagal nerve stimulation - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Summary of clinical studies addressed to invasive cervical vagal nerve stimulation (iVNS) and primary headache disorders

    Journal: Journal of Pain Research

    Article Title: Spotlight on cervical vagus nerve stimulation for the treatment of primary headache disorders: a review

    doi: 10.2147/JPR.S129202

    Figure Lengend Snippet: Summary of clinical studies addressed to invasive cervical vagal nerve stimulation (iVNS) and primary headache disorders

    Article Snippet: In the past two decades, surgically implanted cervical vagal nerve stimulation (iVNS; Cyberonics Inc., TX, USA) was investigated in clinical trials in a broad variety of neurologic disorders such as epilepsy, depression and Alzheimer’s disease.

    Techniques: Functional Assay, Battery

    Summary of clinical studies addressed to non-invasive cervical vagal nerve stimulation (nVNS) for the treatment of episodic and chronic migraine

    Journal: Journal of Pain Research

    Article Title: Spotlight on cervical vagus nerve stimulation for the treatment of primary headache disorders: a review

    doi: 10.2147/JPR.S129202

    Figure Lengend Snippet: Summary of clinical studies addressed to non-invasive cervical vagal nerve stimulation (nVNS) for the treatment of episodic and chronic migraine

    Article Snippet: In the past two decades, surgically implanted cervical vagal nerve stimulation (iVNS; Cyberonics Inc., TX, USA) was investigated in clinical trials in a broad variety of neurologic disorders such as epilepsy, depression and Alzheimer’s disease.

    Techniques: Functional Assay

    Summary of clinical studies addressed to non-invasive cervical vagal nerve stimulation (nVNS) for the treatment of episodic and chronic cluster headache

    Journal: Journal of Pain Research

    Article Title: Spotlight on cervical vagus nerve stimulation for the treatment of primary headache disorders: a review

    doi: 10.2147/JPR.S129202

    Figure Lengend Snippet: Summary of clinical studies addressed to non-invasive cervical vagal nerve stimulation (nVNS) for the treatment of episodic and chronic cluster headache

    Article Snippet: In the past two decades, surgically implanted cervical vagal nerve stimulation (iVNS; Cyberonics Inc., TX, USA) was investigated in clinical trials in a broad variety of neurologic disorders such as epilepsy, depression and Alzheimer’s disease.

    Techniques: Functional Assay

    Schematic drawing of suspected distribution of VPAC1/2 and PAC 1 receptors subtype within the trigeminovascular complex and associated brain circuits. Notes: The parasympathetic neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylate cylase-activating peptide 38 (PACAP-38) interacts with receptor-subtype analysis (VPAC1/2, PAC 1) on a central and peripheral level. Neurogenic dural vasodilatation evoked by dural terminals of trigeminal nerve fibers was suppressed via PAC1-receptor subdomain. Intra-cerebral-ventricular application of PCAP-38, but not VIP, caused delayed activation and central sensitization of spontaneous TCC ring response (mainly via PAC1) along with increased responsiveness to intra- (dural-evoked) and extracranial (cutaneous) stimulation. From Akerman S, Goadsby PJ. Neuronal PAC1 receptors mediate delayed activation and sensitization of trigeminocervical neurons: Relevance to migraine. Sci Transl Med . 2015;7(308):308ra157. Reprinted with permission from AAAS. Abbreviations: SuS, nucleus salivatorius superior; TG, trigeminal ganglion; TCC, trigeminocervical complex; SPG, ganglion sphenopalatinum; PAG, periaquaeductal grey; LC, locus coeruleus; NRM, nucleus raphe magnus; Ach, acetylcholine; NKA, neurokrinin; CGRP, calcitonin gene-related peptide; SP, substance P.

    Journal: Journal of Pain Research

    Article Title: Spotlight on cervical vagus nerve stimulation for the treatment of primary headache disorders: a review

    doi: 10.2147/JPR.S129202

    Figure Lengend Snippet: Schematic drawing of suspected distribution of VPAC1/2 and PAC 1 receptors subtype within the trigeminovascular complex and associated brain circuits. Notes: The parasympathetic neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylate cylase-activating peptide 38 (PACAP-38) interacts with receptor-subtype analysis (VPAC1/2, PAC 1) on a central and peripheral level. Neurogenic dural vasodilatation evoked by dural terminals of trigeminal nerve fibers was suppressed via PAC1-receptor subdomain. Intra-cerebral-ventricular application of PCAP-38, but not VIP, caused delayed activation and central sensitization of spontaneous TCC ring response (mainly via PAC1) along with increased responsiveness to intra- (dural-evoked) and extracranial (cutaneous) stimulation. From Akerman S, Goadsby PJ. Neuronal PAC1 receptors mediate delayed activation and sensitization of trigeminocervical neurons: Relevance to migraine. Sci Transl Med . 2015;7(308):308ra157. Reprinted with permission from AAAS. Abbreviations: SuS, nucleus salivatorius superior; TG, trigeminal ganglion; TCC, trigeminocervical complex; SPG, ganglion sphenopalatinum; PAG, periaquaeductal grey; LC, locus coeruleus; NRM, nucleus raphe magnus; Ach, acetylcholine; NKA, neurokrinin; CGRP, calcitonin gene-related peptide; SP, substance P.

    Article Snippet: In the past two decades, surgically implanted cervical vagal nerve stimulation (iVNS; Cyberonics Inc., TX, USA) was investigated in clinical trials in a broad variety of neurologic disorders such as epilepsy, depression and Alzheimer’s disease.

    Techniques: Activation Assay